Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
arborpharma.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$34.8M

About Arbor Pharmaceuticals

Arbor Pharmaceuticals is a specialty pharmaceutical company currently focused on the cardiovascular, hospital and pediatric markets.On August 24th, 2021, Arbor Pharmaceuticals was acquired by Azurity Pharmaceuticals. Terms of the transaction were not disclosed.

Arbor Pharmaceuticals Headquarter Location

6 Concourse Parkway Suite 1800

Atlanta, Georgia, 30328,

United States

678-334-2420

Latest Arbor Pharmaceuticals News

Esmethadone effective for patients with major depressive disorder

Jan 4, 2022

Disclosures: Fava reports grant support from Relmada Therapeutics during this study; he has received grant support from Acadia Pharmaceuticals, Aditum Bio Management Company, Allergan, Alkermes, Altimate Health Corporation, Angelini S.p.A, Aptinyx, Arbor Pharmaceuticals, Avanir Pharmaceuticals, Axsome, Benckiser Pharmaceuticals, BioClinica, Biogen, BioHaven, Cambridge Science Corporation, Cerecor, Gate Neurosciences, GenOmind, Gentelon, Happify, Johnson & Johnson, Lundbeck, Marinus Pharmaceuticals, Methylation Sciences, Millennium Pharmaceutics, Minerva Neurosciences, the National Institute of Drug Abuse, Neuralstem, NeuroRX, NIH, NIMH, Novartis, Otsuka, the Patient-Centered Outcomes Research Institute, Pfizer, Premiere Research International, Protagenic Therapeutics, Relmada Therapeutics, Reckitt, Shenox Pharmaceuticals, Stanley Medical Research Institute, Taisho, Takeda, the University of Michigan, and Vistagen; he is a shareholder with Compellis and Psy Therapeutics; he has a patent and/or royalties and has received other income for sequential parallel comparison design, licensed by Massachusetts General Hospital (MGH) to Pharmaceutical Product Development; he has a patent application for a combination of ketamine plus scopolamine in major depressive disorder, licensed by MGH to Biohaven; he holds a copyright for the MGH Cognitive and Physical Functioning Questionnaire, the Sexual Functioning Inventory, the Antidepressant Treatment Response Questionnaire, the Discontinuation-Emergent Signs and Symptoms, the Symptoms of Depression Questionnaire, and SAFER; and he receives royalties from Lippincott Williams & Wilkins, Wolters Kluwer, and World Scientific Publishing. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Esmethadone produced fast and consistent positive outcomes in patients for whom previous treatments for depression were not effective, according to a randomized, double-blind study published in the American Journal of Psychiatry. “In this study, we hypothesized that REL-1017 would confirm, in patients with major depressive disorder, the favorable tolerability, safety and pharmacokinetic profiles observed in phase 1 trials,” Maurizio Fava, MD, of the department of psychiatry at Massachusetts General Hospital, and colleagues wrote. “Additionally, based on available preclinical and clinical data, we hypothesized that REL-1017 would provide rapid-onset and effective treatment for patients with major depressive disorder.” Fava and colleagues sought to examine the impact of esmethadone , also known as REL-1017 (Relmada Therapeutics Inc.), a novel N-methyl-Daspartate receptor (NMDAR) channel blocker, in patients diagnosed with major depressive disorder who showed no positive effects when previously prescribed anywhere from one to three standard antidepressants during a major depressive episode. The researchers conducted a weeklong phase 2 multicenter randomized, double-blind, placebo-controlled trial, comprising three segments, to assess the effects of two different dosages of esmethadone. Among the 62 patients, 34 were male and 28 female, all were aged 18 to 65 years and had experienced a major depressive episode lasting 8 weeks to 36 months. Patients were randomly assigned on an equal basis to be given either a placebo, 25 mg per day or 50 mg per day of esmethadone. Fifty-seven patients finished the trial. The primary efficacy endpoint for the study was the Montgomery-Åsberg Depression Scale (MADRS) score. Results showed that patients experienced mild or moderate adverse events that passed quickly and the treatment produced no evidence of dissociative or psychotic behaviors , nor any signs or symptoms of withdrawal. Improvement in MADRS score began on the fourth day of the trial within both esmethadone dosage groups, was sustained through the sevemth day in which the last dose was given, then extended until 7 days after administration of the final dose. The researchers wrote that the results will require further confirmation through subsequent, longer trials that examine drug efficacy in larger sample sizes. “In summary, in this phase 2a trial in patients with major depressive disorder and inadequate responses to antidepressant treatments, REL-1017 confirmed favorable safety, tolerability and pharmacokinetic profiles and showed a robust signal for rapid and sustained antidepressant effects that warrant confirmation in longer trials,” Fava and colleagues wrote. Read more about

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Arbor Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Arbor Pharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

S

Sleep Health & Wellness

798 items

These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.

Arbor Pharmaceuticals Patents

Arbor Pharmaceuticals has filed 30 patents.

The 3 most popular patent topics include:

  • Prodrugs
  • Calcium channel blockers
  • Food additives
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/20/2019

12/28/2021

Vascular diseases, Calcium channel blockers, Hypertension, Carboxylate esters, Ethers

Grant

Application Date

12/20/2019

Grant Date

12/28/2021

Title

Related Topics

Vascular diseases, Calcium channel blockers, Hypertension, Carboxylate esters, Ethers

Status

Grant

Arbor Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Arbor Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.